| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| Gene symbol | MS4A1 | Synonyms | B1, Bp35, CD20, CVID5, FMC7, LEU-16, S7 | Type of gene | protein-coding |
| Chromosome | 11 | Map location | 11q12.2 | dbXrefs | |
| Description | membrane spanning 4-domains A1 | ||||
| GTO ID | GTC3905 |
| Trial ID | NCT06462144 |
| Disease | Systemic Lupus Erythematosus | Vasculitis | Idiopathic Inflammatory Myopathy |
| Altered gene | CD19|CD20 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | IMPT-514 |
| Phase | Early_Phase1 |
| Recruitment status | Not Recruiting |
| Title | An Exploartory Trial of IMPT-514, An Autologous Anti-CD19/20 CAR T Therapy in Participants With Active, Refractory Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy |
| Year | 2024 |
| Country | China |
| Company sponsor | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
| Other ID(s) | RD17-01 |
| Cohort 1 | |||||||||||
|
|||||||||||